News >

Sznol Highlights Immunotherapy Advances in RCC

Brandon Scalea
Published: Wednesday, Mar 20, 2019

Dr. Mario Sznol

Mario Sznol, MD
With the combination of PD-1 inhibitors and VEGF TKIs now poised to move into the frontline setting for patients with metastatic renal cell carcinoma (mRCC), the field has significantly evolved over the last decade. However, the next steps in achieving even more durable responses are unclear, said Mario Sznol, MD.

, Sznol, professor of medicine and co-director of the Cancer Immunology Program and the Yale SPORE in Skin Cancer at Yale Cancer Center, highlighted recent advances made with immunotherapy in RCC and shed light on what the future may hold.

OncLive: What are the key data supporting an immunotherapy approach in mRCC?

Sznol: There are 2 or 3 key trials. CheckMate-214 compared ipilimumab and nivolumab to sunitinib, showing that at least in a subset of mRCC—the intermediate- and poor-risk group—the combination improved survival compared with TKI monotherapy. That is probably the major trial in our field. It's clear that anti–PD-1 alone is active in this setting, but it isn't clear yet whether or not the combination is better than anti–PD-1 by itself. The randomized trial data are clearly [in favor of] the combination. We also have a dosing schedule that is really well tolerated.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x